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Risk sharing and managed entry agreements: The context in which they arise 
 
Stretched health care budgets, increasing availability of potentially life-saving high-cost drugs and 
increasing patient expectations, mean that manufacturers seeking inclusion in reimbursement lists 
need to demonstrate that their drugs can provide additional benefit in comparison with best 
available standards of care and value-for-money in order to obtain coverage. 
Countries increasingly try to achieve this by using health technology assessment (HTA) as a tool to 
evaluate the clinical and cost-effectiveness of new drugs. However, data and the overall evidence 
base available at registration are increasingly inadequate to accurately estimate the clinical and cost-
effectiveness of a drug in clinical practice or its budget impact in real life. Uncertainty, due to lack of 
information on (comparative) effectiveness, may delay coverage decisions and patient access.  
Against this background, formal arrangements between payers and manufacturers with the aim of 
apportioning risk due to uncertainty surrounding the introduction of new technologies have been 
introduced to facilitate access to new medicines. These agreements can take different forms, 
including price-volume agreements (PVAs), outcome guarantee, coverage with evidence 
development (CED), and disease management programmes, to name but a few. A variety of names 
have been used to describe these schemes (e.g. risk-sharing agreements (RSAs), performance-based 
agreements (PBAs), patient access schemes (PAS), etc.), which have been recently summarised with 
the concept of “manage entry agreements (MEAs)” (Klemp, Frønsdal, Facey, and HTAi Policy Forum 
2011; Ferrario and Kanavos, EMINet 2013) 
Over time, there has been a proliferation of managed entry schemes focusing, among other things, 
on price, utilisation and health outcomes.   
The LSE Summit: 14 February 2014 
The Medical Technology Research Group (MTRG) at LSE Health is delighted to organise and host a 
one-day summit on Risk Sharing and Managed Entry Agreements (MEAs) on 14th February 2014.  
During the summit, leading experts from academia, policy-making, industry and the patient 
community will convey their experience with the implementation of MEAs in different settings, 
assess the emerging evidence on schemes such as coverage with evidence development and 
outcomes-based risk-sharing and reflect on policy options for the future.  
Delegates can expect high calibre speakers from several countries implementing MEAs / risk-sharing 
agreements. Presentations will enable delegates to learn about the latest developments in the field, 
gain insights on implementing MEAs from different stakeholder perspectives, including a primer on 
collaborative approaches to coverage decisions, and debate the necessary conditions for the wider 
implementation of outcomes-based risk-sharing in the future. Delegates will also have the 
opportunity to network, exchange views and perspectives and become part of the LSE academic 
community. 
Panellists will feature representatives from the Dutch Health Care Insurance Board, Myeloma UK, 
Oxford University, the Swedish Dental and Pharmaceutical Benefits Board (TLV), the Italian 
Medicines Agency (AIFA), the European Commission and the Organization for Economic 
Development and Cooperation (OECD). 
The summit is sponsored by Ernst and Young, with The Financial Times being the media 
partner. 
Date: 14 February 2014, 9am-5pm  
Venue: The Royal College of Surgeons, Lecture Theatre Two, 35-43 Lincoln's Inn Fields, 
London WC2A 3PE, UK  
Programme and registration 
For more information please contact: Panos Kanavos or Alessandra Ferrario 
Panos Kanavos (BSc, MSc (Oxon), MSc (LSE), PhD) is Reader in International Health Policy in 
the Department of Social Policy, London School of Economics (LSE) and Programme Director 
of the Medical Technology Research Group (MTRG) at LSE Health. 
Alessandra Ferrario (BSc, MSc (University of Basel), MSc (LSE/LSHTM)) is a Research Officer 
in health and pharmaceutical policy at LSE Health and a PhD candidate in the Department of 
Social Policy. 
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